Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.57 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637660 | 0.93 | ELANE (0.58) | ELANECTRB1CTSKTAAR1CYP17A1 | |
| SCHEMBL6638450 | 0.93 | CTRB1 (0.55) | ELANECTRB1CTSK | |
| SCHEMBL6634622 | 0.90 | CTRB1 (0.56) | ELANECTRB1 | |
| SCHEMBL6636920 | 0.86 | CTRB1 (0.52) | ELANECTRB1CTSKTAAR1CYP17A1 | |
| SCHEMBL6635647 | 0.86 | ELANE (0.60) | ELANECTRB1 | |
| SCHEMBL6639590 | 0.86 | CTRB1 (0.56) | ELANECTRB1P2RX7 | |
| SCHEMBL6639124 | 0.86 | ELANE (0.57) | ELANECTRB1 | |
| SCHEMBL6637344 | 0.85 | ELANE (0.51) | ELANECTRB1CYP17A1 | |
| SCHEMBL6636428 | 0.84 | ELANE (0.57) | ELANECTRB1CYP17A1 | |
| SCHEMBL6636149 | 0.81 | CTRB1 (0.53) | ELANECTRB1CYP17A1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116420-A1 | Remedial agent for viral infectious disease | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1403269-A1 | REMEDIAL AGENT FOR VIRAL INFECTIOUS DISEASE | Asahi Kasei Pharma Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |